331744-64-0

Basic information

• Product Name: Peliglitazar
• Synonyms: Peliglitazar
• CAS NO: 331744-64-0
• Molecular Formula: C₃₀H₃₀N₂O₇
• Molecular Weight: 530.574
• Mol File: 331744-64-0.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 733.1°C at 760 mmHg
• Flash Point: 397.2°C
• Appearance: /
• Density: 1.255g/cm³
• Vapor Pressure: 1.46E-22mmHg at 25°C
• Refractive Index: 1.594
• CAS DataBase Reference: Peliglitazar(CAS DataBase Reference)
• NIST Chemistry Reference: Peliglitazar(331744-64-0)
• EPA Substance Registry System: Peliglitazar(331744-64-0)

Safety Data

• Hazardous Substances Data: 331744-64-0(Hazardous Substances Data)

Usage

Description

Peliglitazar is a dual peroxisome proliferator-activated receptor (PPAR) agonist, which means it activates both PPAR-alpha and PPAR-gamma receptors. It is a pharmaceutical compound that has been developed for the treatment of various metabolic disorders. Its dual agonist action allows it to regulate multiple pathways involved in glucose and lipid metabolism, making it a promising candidate for the treatment of complex metabolic conditions.

Uses

Used in Pharmaceutical Industry:
Peliglitazar is used as an anti-diabetic agent for the treatment of Type II diabetes mellitus. It helps in regulating blood sugar levels by enhancing insulin sensitivity and promoting glucose uptake in the body.
Peliglitazar is also used as a treatment for mixed dyslipidemia, a condition characterized by abnormal levels of cholesterol and other fats in the blood. Its dual PPAR agonist action helps in improving lipid profiles by reducing triglycerides, increasing high-density lipoprotein (HDL) cholesterol, and lowering low-density lipoprotein (LDL) cholesterol levels.
Additionally, Peliglitazar is used for the treatment of atherosclerosis, a condition where plaque builds up inside the arteries, leading to reduced blood flow and an increased risk of heart attack or stroke. By improving lipid profiles and reducing inflammation, Peliglitazar can help slow down the progression of atherosclerosis.
Furthermore, Peliglitazar is used in the management of metabolic syndrome, a cluster of conditions that increase the risk of heart disease, stroke, and diabetes. Its dual agonist action helps in addressing multiple components of metabolic syndrome, including insulin resistance, high blood pressure, and abnormal cholesterol levels, thereby reducing the overall risk of developing these chronic conditions.

InChI:InChI=1/C30H30N2O7/c1-20(32(19-28(33)34)30(35)39-26-15-13-24(36-3)14-16-26)22-9-11-25(12-10-22)37-18-17-27-21(2)38-29(31-27)23-7-5-4-6-8-23/h4-16,20H,17-19H2,1-3H3,(H,33,34)/t20-/m0/s1

Downstream Products

• 951754-64-6 peliglitazar